Template-fixed peptidomimetics with antimicrobial activity
US-9521846-B2 · Dec 20, 2016 · US
US10730912B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10730912-B2 |
| Application number | US-201615392586-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 28, 2016 |
| Priority date | Jan 16, 2006 |
| Publication date | Aug 4, 2020 |
| Grant date | Aug 4, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Template-fixed β-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa . They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.
Opening claim text (preview).
The invention claimed is: 1. A compound represented by the following formula (I): is D Pro- L Pro or L Pro- D Pro and Z is a chain of 12 α-amino acid residues, wherein the positions of the amino acid residues in the chain are counted starting from the N-terminal amino acid, wherein the amino acid residues in positions P1 to P12 of the chain are Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Gly, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, D Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, D Val, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Aib, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Abu, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Leu, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ile, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Nle, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Nva, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Chg, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Cha, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Gln, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Asp; Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Glu, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Thr, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Pro, Dab; Cit, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Tyr, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Tyr, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, His, Trp, Dab, Dab, Ala, Dab; Ala, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Ala, Trp, Ile, Dab, Dab, Dab, Dab, Trp, Dab, Dab, Val, Dab; Thr, Trp, Ile, Lys, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Lys, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Lys, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Lys, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Lys; Thr, Trp, Ile, Gln, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Gln, Lys, Dab, Dab, Trp, Dab, Dab, Val, Dab; Thr, Trp, Nle, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Val, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Chg, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Cha; Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Hse, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, t-BuG, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Cpa, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Asn, Dab; Thr, Trp, Ile, Dab, Lys, Dab, Gln, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Gln, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Gln; Thr, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab; Asp, Tyr, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab; Asp, Tyr, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab; Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab; Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Gln; Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dap; Glu, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab; Thr, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Ser; or Glu, Trp, Ile, Gln, Lys, Dab, Dab, Ser, Dab, Dab, Ala, Ser, or a pharmaceutically acceptable salt or enantiomer thereof. 2. An enantiomer of the compound of claim 1 or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, which is therapeutically active. 4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, which has selective antimicrobial activity against Pseudomonas aeruginosa. 5. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically inert carrier. 6. The pharmaceutical composition of claim 5 , which is in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary, or inhalation administration. 7. The pharmaceutical composition of claim 5 , which is in the form of a tablet, dragee, capsule, solution, liquid, gel, plaster, cream, ointment, syrup, slurry, suspension, spray, nebuliser, or suppository.
Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof · CPC title
having 5 to 11 amino acids · CPC title
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55}) · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Ophthalmic agents · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.